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Graft dysfunction in chronic antibody-mediated
rejection correlates with B-cell–dependent indirect
antidonor alloresponses and autocrine regulation
of interferon-g production by Th1 cells
Kin Yee Shiu1,3, Laura McLaughlin1, Irene Rebollo-Mesa1,4, Jingyue Zhao1, Hannah Burton1,
Harriet Douthwaite1, Hannah Wilkinson1, Vikki Semik1, Philippa C. Dodd1, Paul Brookes2,
Robert I. Lechler1, Maria P. Hernandez-Fuentes1, Claudia Kemper1 and Anthony Dorling1
1MRC Centre for Transplantation, King’s College London, Guy’s Hospital, London, UK; and 2Imperial College London and Imperial College
NHS Trust, Hammersmith Hospital, London, UK
Chronic antibody-mediated rejection, a common cause of
renal transplant failure, has a variable clinical phenotype.
Understanding why some with chronic antibody-mediated
rejection progress slowly may help develop more effective
therapies. B lymphocytes act as antigen-presenting cells
for in vitro indirect antidonor interferon-g production in
chronic antibody-mediated rejection, but many patients
retain the ability to regulate these responses. Here we test
whether particular patterns of T and B cell antidonor
response associate with the variability of graft dysfunction
in chronic antibody-mediated rejection. Our results
conﬁrm that dynamic changes in indirect antidonor CD4D
T-cell responses correlate with changes in estimated
glomerular ﬁltration rates, independent of other factors.
Graft dysfunction progressed rapidly in patients who
developed unregulated B-cell–driven interferon-g
production. However, conversion to a regulated or
nonreactive pattern, which could be achieved by
optimization of immunosuppression, associated with
stabilization of graft function. Functional regulation by B
cells appeared to activate an interleukin-10 autocrine
pathway in CD4D T cells that, in turn, impacted on
antigen-speciﬁc responses. Thus, our data signiﬁcantly
enhance the understanding of graft dysfunction
associated with chronic antibody-mediated rejection and
provide the foundation for strategies to prolong renal
allograft survival, based on regulation of interferon-g
production.
Kidney International (2017) 91, 477–492; http://dx.doi.org/10.1016/
j.kint.2016.10.009
KEYWORDS: B lymphocyte; chronic allograft nephropathy; ELISPOT; indirect
alloresponses; interferon-g
Copyright ª 2016, International Society of Nephrology. Published by
Elsevier Inc. All rights reserved.
K idney transplantation is the best treatment for kidneyfailure, in terms of length and quality of life and cost-effectiveness,1,2 but a signiﬁcant number of patients
keep their transplants for less than 10 years,3 returning to
dialysis as the transplant fails. The single biggest cause is
immune-mediated injury.4 The association between antibody
(Ab) against donor human leukocyte antigen (HLA) (donor-
speciﬁc Ab [DSA]) and graft failure,5 and description of
speciﬁc histological features constituting antibody-mediated
rejection (AMR),6 have advanced our understanding of this
problem. Graft failure is usually preceded by a progressive
decline in glomerular ﬁltration rate (GFR), although many
patients with DSA have stable graft function, and the
immunological factors that inﬂuence decline in GFR are
unknown.
We recently reported the ﬁndings of a long-term obser-
vational study in patients with a transplant biopsy diagnosis
of chronic AMR (CAMR),7 describing the activity of anti-
donor T cells recognizing donor antigen via the indirect
pathway.8 For the ﬁrst time, we showed that donor antigen
presentation by B cells in enzyme-linked immunosorbent
spot (ELISPOT) assays of interferon (IFN)-g production by
CD8-depleted peripheral blood mononuclear cells (PBMCs)
was seen preferentially in patients with CAMR compared with
controls. Importantly, two-thirds of nonreactive samples had
evidence of suppression of antidonor IFN-g production by
CD19þ B lymphocytes or CD25þ T cells, challenging the
prevalent hypothesis that patients with chronic rejection have
lost the ability to regulate antidonor cellular immunity.9 In
this report, we expand our ﬁndings from the same cohort
by describing the dynamic changes in ELISPOT patterns in
individual patients and report an association with changes in
estimated GFR (eGFR), testing the hypothesis that progres-
sion of renal dysfunction is inﬂuenced by the activity of
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antidonor cell-mediated responses. We provide evidence of
the predictive accuracy of ELISPOT, above that provided by
other clinical factors alone. Finally, in attempting to
demonstrate the role of interleukin (IL)-10 in patients with
regulated ELISPOT responses, we discovered evidence that B
cells activated a well-deﬁned IL-10 autocrine regulatory
mechanism in T helper 1 (Th-1) cells, which was involved in
suppressing antidonor responses. Further investigation of the
importance of cellular immune responses in AMR may pro-
mote a deeper understanding of how to treat chronic
rejection.
RESULTS
Patient groups and outcomes
This report concerns 52 patients included in our recent
publication7 who had either a protocol (PROTCL, n ¼ 15) or
“for-cause” biopsy (BFC, n ¼ 37). Reasons for exclusions and
relevant details of those included are provided in the
Supplementary Material. Blood samples were collected within
a month of biopsy (time point 1) and 9 to 12 months later
(time point 2) for analysis of DSA and antidonor IFN-g
responses. There were no graft failures in the PROTCL group,
whereas 11 grafts from the BFC group failed. There was no
statistically signiﬁcant difference in median eGFR at time of
ﬁrst ELISPOT between the 11 who had graft failure (39.3
ml/min per 1.73 m2 [interquartile range (IQR) 16.8]) and the
other 41 who maintained graft function during the course of
the study (45.7 ml/min per 1.73 m2 [IQR 23.9] P ¼ 0.1
Mann-Whitney U test). To assist interpretation of some
analyses, changes in eGFR (DeGFR) were dichotomized into
“deteriorating” (n ¼ 27) and “stable” (n ¼ 25), based on
relationship to the median in each of the PROTCL or BFC
groups (Figure 1, Supplementary Tables S1B and S1C), and
the 2 subgroups created had statistically signiﬁcant differences
in DeGFR, despite having similar eGFRs at the time of ﬁrst
ELISPOT (Supplementary Tables S1B and S1C). All 11
patients who lost graft function were in the “deteriorating”
subgroup.
Associations with DeGFR
Proteinuria, biopsy features, and DSA (Table 1). Proteinuria
at the time of biopsy was strongly associated with graft failure,
and a protein-to-creatinine ratio>50 was a sensitive marker of
graft failure, whereas protein-to-creatinine ratio <50 was
highly predictive of graft survival (see legend to Table 1).
Protein-to-creatinine ratio was also associated with DeGFR,
although was relatively insensitive and poorly predictive of
whether a patient was “stable” or “deteriorating.” Two speciﬁc
biopsy features were associated with graft failure, but both
appeared relatively insensitive and poorly predictive within the
follow-up period. There was no association between DeGFR
and either of these biopsy features (Supplementary Figure S1
and Supplementary Table S2). The mean ﬂuorescence in-
tensities of serum DSA and lack of association with ELISPOT
activity were presented in Shiu et al.7 DSAs were associated
with graft failure, but with poor sensitivity, and although they
were also associated with DeGFR at time point 1
(Supplementary Figure S2), they could not discriminate be-
tween stable and deteriorating subgroups, all suggesting that
DSA presence was not sensitive, predictive, or relatively speciﬁc
at discriminating patients with outcomes based on DeGFR.
ELISPOT patterns (Tables 2–5). Donor-speciﬁc reactivity
(DSR) was deﬁned as antidonor reactivity above threshold
(see Tables 2 and 3) by CD8-depleted PBMCs in IFN-g
ELISPOT assays, after incubation with whole donor-derived
proteins, whereas no DSR (NDSR) refers to a subthreshold
response. Tables 2 and 3 show the different types of patterns
obtained and the numbers of samples with each pattern at
time points 1 and 2. In the whole cohort, the greatest loss of
GFR was seen in patients with DSR at time point 2 (Figure 2a)
and approximately 65% of patients with DSR at this time
point appeared in the “deteriorating subgroup”; these
relationships just failed to reach statistical signiﬁcance.
However, when analyzed separately, DSR at time point 2 was
associated with deterioration in the BFC but not the PROTCL
subgroup (Supplementary Figure S3 and Supplementary
Table S3).
ELISPOT patterns also could be deﬁned according to
functional B-cell phenotype and in particular whether
there was evidence of a B-cell–dependent antidonor response.
Using this deﬁnition, associations between DeGFR and
ELISPOT patterns were maintained (Figure 2b, Table 5).
Subgroup analysis suggested a strengthening of associations in
the PROTCL patients at time point 1, whereas in the BFC
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Figure 1 | DeGFR in PROTCL and BFC subgroups and combined
group. Box plots show median and IQR, with whiskers representing
data within 1.5 the IQR of the upper and lower quartiles, with outliers
>1.5 and <3.0 IQR as þ and >3.0 IQR as *. Horizontal lines to right of
box plots indicate the mean value. Nine patients with BFC who either
had missing follow-up data (n ¼ 2), or eGFR <20 ml/min per 1.73 m2
at time of biopsy (n ¼ 7) have been excluded (Supplementary
Table S1c). The “combined” group includes all patients with PROTCL
and BFC, and have been split into “deteriorating” and “stable” sub-
groups, based on the relationship to the median DeGFR in each of the
PROTCL and BFC subgroups. *Deteriorating group contains patients
with DeGFR below or equal to the median in each of PROTCL and BFC
groups (n ¼ 27). The median DeGFR in this subgroup is 14.4 ml/min
per 1.73 m2 (IQR 15.5). Stable group contains patients with DeGFR
above the median from each of the PROTCL and BFC groups (n ¼ 25).
The median DeGFR for this group is 0.3 ml/min per 1.73 m2 (IQR 6.0).
**Mann-Whitney U test.
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subgroup, associations at time point 2 were weakened and
failed to reach statistical signiﬁcance (Supplementary
Figure S4 and Supplementary Table S4).
Multivariate logistic regression analysis. The independent
predictive value of the ELISPOT assay at time point 1 was
considered separately in PROTCL and BFC subgroups, by
comparison with other factors potentially associated with graft
dysfunction. We estimated a series of multivariate logistic
regression models, each of which included groups of related
predictive variables: demographics, recipient factors from time
of transplantation, donor factors, HLA antibody, protocol bi-
opsy features, and ELISPOT results (Supplementary Tables S5
and S6). The probability of graft dysfunction as estimated by
each of the models was then used to build receiver operator
characteristic curves to evaluate performance differences
across the different models. In the PROTCL group, ELISPOT
assay results alone were able to predict development of
graft dysfunction better than any other set of risk factors
(Supplementary Table S5). Subsequently, elastic net with
leave-group-out cross-validation was used to select the optimal
model for classiﬁcation, considering all predictors in a com-
bined model. Results showed that a predictive algorithm that
included B-dependent DSR (from the ELISPOT assay) as the
only predictor provided the best performance, with an area
under the curve (AUC) of 0.84 (95% conﬁdence interval 0.61–
1, speciﬁcity 0.88, sensitivity 0.80) (Figure 3a). The cross-
validated estimate of the AUC was 0.89.
A similar approach was used for the BFC subgroup
(Supplementary Table S6), but the optimal model generated
by elastic net and leave-group-out cross-validation identiﬁed
5 factors, including B-dependent DSR on ELISPOT assay (the
others were HLA Ab status [including DSA mean ﬂuorescence
intensity at time of biopsy], C4d in peritubular capillaries
(PTC), degree of interstitial ﬁbrosis/tubular atrophy (IF/TA)
on biopsy, and proteinuria). This combined model produced
a receiver operating characteristic curve with an AUC of 0.85
(95% conﬁdence interval 0.72–1) with a peak of 89% sensi-
tivity and 77% speciﬁcity, which was better than any of the
individual models (Figure 3b). The cross-validated estimate of
the AUC was 0.73. These data indicate that the patterns of
Table 1 | Associations between clinical and biopsy features, DSA and patient outcomes
Clinical variable
Result in whole
cohort
Number of biopsies/samples
Pa
Number of biopsies/samples
PaGraft failure No graft failure
Deteriorating eGFR
(£median)
Stable eGFR
(>median)
PCR >50 at time of biopsy Yes (n ¼ 25) 10 15 0.002 17 8 0.03
No (n ¼ 27) 1 26 10 17
Biopsy subgroup BFC (n ¼ 37) 11 26 0.02 19 18 1
PROTCL (n ¼ 15) 0 15 8 7
Gross biopsy features AMR (n ¼ 45) 11 34 0.3 25 20 0.24
Control (n ¼ 7) 0 7 2 5
Tubulitis Positive (n ¼ 4) 2 2 0.2 3 1 0.6
Negative (n ¼ 48) 9 39 24 24
C4d (PTC) Positive (n ¼ 26) 8 18 0.1 16 10 0.27
Negative (n ¼ 26) 3 23 11 15
C4d (g) Positive (n ¼ 30) 9 21 0.09 17 13 0.58
Negative (n ¼ 22) 2 20 10 12
G score $1 (n ¼ 21) 6 15 0.3 14 7 0.1
0 (n ¼ 31) 5 26 13 18
PTC score $1 (n ¼ 15) 7 8 0.008 8 7 1
0 (n ¼ 37) 4 33 19 18
CG score $1 (n ¼ 20) 7 13 0.08 10 10 1
0 (n ¼ 32) 4 28 17 15
CV score $1 (n ¼ 22) 6 16 0.5 13 9 0.57
0 (n ¼ 29) 5 24 14 15
% Median IF/TA score 30 15 <0.05b 20 15 >0.05
DSA time point 1 >1000 (n ¼ 18) 7 11 0.03 12 6 0.15
0 or <1000 (n ¼ 34) 4 30 15 19
DSA time point 2 >1000 (n ¼ 18) 7 11 0.04 11 7 0.39
0 or <1000 (n ¼ 32) 4 28 15 17
DSA overallc >1000 (n ¼ 20) 7 13 0.08 12 8 0.4
0 or <1000 (n ¼ 32) 4 28 15 17
Proteinuria: Graft failure – Sensitivity: 10/11 ¼ 91%; PPV: 10/25 ¼ 40%; NPV: 26/27 ¼ 96%; Speciﬁcity: 26/41 ¼ 63%.
Proteinuria: Deteriorating function – Sensitivity: 17/27 ¼ 63%; PPV 17/25 ¼ 68%; NPV 17/27 ¼ 63%; Speciﬁcity 68%.
PTC score: Graft failure – Sensitivity: 7/11 ¼ 64%; PPV: 7/15 ¼ 67%; NPV: 33/37 ¼ 89%; Speciﬁcity: 33/41 ¼ 80%.
DSA >1000 time point 1: Graft failure – Sensitivity: 7/11 ¼ 64%; PPV: 7/18 ¼ 39%; NPV: 30/34 ¼ 88%; Speciﬁcity: 30/41 ¼ 77%.
DSA >1000 time point 2: Graft failure – Sensitivity: 7/11 ¼ 64%; PPV: 7/18 ¼ 39%: NPV: 28/32 ¼ 88%; Speciﬁcity: 28/39 ¼ 72%.
Bold P values are statistically signiﬁcant.
AMR, antibody-mediated rejection; BFC, for-cause biopsy; DSA, donor-speciﬁc antibody; eGFR, estimated glomerular ﬁltration rate; NPV, negative predictive value; PCR,
protein-to-creatinine ratio; PPV, positive predictive value; PROTCL, protocol; PTC, peritubular capillary; g, glomerulitis; cg/cv, BANFF chronic glomerulopathy and vascular
scores; IF/TA, interstitial ﬁbrosis/tubular atrophy.
aFisher exact test.
bMann-Whitney U test.
cDSA at either time point 1 or 2 or both.
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antidonor T-cell IFN-g production, from around the time of
biopsy, do have prognostic inﬂuence on progression of renal
dysfunction, particularly in the PROTCL group.
Dynamic changes in antidonor IFN-g production and
association with eGFR
Loss of responsiveness/regulation and dysfunction. In
contrast to when individual time points were considered in
isolation, changes in antidonor ELISPOT reactivity in
individuals were strongly associated with DeGFR (Tables 4
and 5). To assess this further, we estimated generalized
linear mixed models separately for those patients from the
BFC cohort (with 2 viable ELISPOT samples), who were
NDSR (Figure 4a) or DSR (Figure 4b) at time of biopsy.
Results showed a statistically signiﬁcant interaction between
the presence of DSR on follow-up samples, and the time of
eGFR assessment in both groups (P ¼ 0.003 for baseline
NDSR, and P ¼ 0.0001 for baseline DSR, respectively),
indicating that the change in antidonor responses was
signiﬁcantly associated with different patterns of eGFR over
time. Remarkably, Figure 4b shows how those patients who
had DSR at baseline, but then changed to NDSR, maintained
stable function, as opposed to those who remained DSR and
showed signiﬁcant decline. Similarly, patients who developed
DSR over follow-up, showed a steeper decline than those who
remained DSR negative (Figure 4a).
To assess the whole cohort, and to further address the
importance of B-cell phenotype, we performed an analysis of
changes in individual patients who had 2 interpretable
ELISPOTs. A detailed descriptive analysis is provided in the
supplementary ﬁle (Results section and Supplementary
Table S7) and only a concise interpretation is presented
here (Table 6). This analysis showed a signiﬁcant association
between maintenance of nonreactivity or development of
regulated donor reactivity at time point 2 and graft stability
(Fisher exact P ¼ 0.0417). When analyzed by DeGFR, the
differences between these groups was signiﬁcant (Figure 4c).
These associations between antidonor ELISPOT pattern
changes and eGFR were antigen speciﬁc, as an analysis of the
responses to control cytomegalovirus and varicella-zoster
virus proteins revealed no signiﬁcant associations with
DeGFR (Figure 4d), despite the antiviral antigen ELISPOT
patterns themselves showing similar changes as those to
antidonor proteins (Supplementary Tables S8 and S9).
Altogether, these data support the conclusion that a change
from a nonresponsive or regulated antidonor response to
unregulated, B-cell–dependent antidonor IFN-g production
is associated with a signiﬁcant decline in eGFR.
Table 2 | ELISPOT patterns, classiﬁed by response to donor antigens when CD8D cells depleted as DSR or NDSR and, for the
latter by the response after depletion of CD25D cells (“Treg”) or CD19D cells (Breg)
ELISPOT patterns Interpretation
based on reactivity
of CD8-depleted
PBMC (DSR) versus
nonreactivity
(NDSR)a
Interpretation based on
B-cell phenotype
CD25 present CD25 depleted
CD8-deplete
CD8- and
CD19-deplete CD8-deplete
CD8 and
CD19-deplete
    NDSR No regulation No regulation No response
 þb   Breg Breg: only when CD25þ
cells present
Regulated antidonor response
without evidence
of B-dependency þ  þ Breg: when CD25þ cells present
or absent
   þ Treg, Breg Breg: only when CD25þ cells
absent
 þ þ  Breg when CD25 present BUT Bdep
when CD25 absent
B-dependent antidonor response
with evidence of regulation
  þ  Treg Bdep: only when CD25þ cells
absent
þ   þ DSR Bdep Bdep when CD25 present, Breg when
CD25þ cells absent
þ  þ  Bdep: when CD25þ cells present
and absent
Unregulated B-dependent
antidonor response
þ    Bdep: only when CD25þ cells
present
An alternative way to interpret these patterns is by the functional B-cell phenotype in the presence or of CD25þ cells. Note that some samples deﬁned in Shiu et al.7 as DSR
Bdep showed evidence of Breg activity in absence of CD25þ cells.
Bdep, decrease in spot count of $20% when CD19þ cells depleted; Breg, increase in spot count of $20% when CD19þ cells depleted; DSR, donor-speciﬁc reactivity; ELISPOT,
enzyme-linked immunosorbent spot;NDSR, nodonor-speciﬁc reactivity; PBMC,peripheral bloodmononuclear cell; Treg, increase in spot countof$20%whenCD25þ cells depleted.
aAs used in Shiu et al.7
bThreshold for deﬁning positive antidonor interferon-g production was 25 or more spots per million CD4þ cells on donor antigen plate compared with background.
Therefore, “þ” ¼ spot count $25; “” ¼spot count <25.
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Table 3 | Number of samples ELISPOT patterns interpreted by B-cell phenotype in PROTCL and BFC by time
Interpretation based on B-cell phenotype
Number of ELISPOTs
showing the deﬁned pattern
PROTCL BFC Total
Time point 1 Time point 2 Time point 1 Time point 2 Time point 1 Time point 2
No evidence of B-dependent
antidonor response
No response No regulation 3 1 5 11 8 12
Evidence of
regulation
Regulated antidonor
response without
evidence of B-dependency
Breg: only when CD25þ
cells present
2 2a 0 1
5 7Breg: when CD25þ cells present
and absent
0 2 2 0
Breg: only when CD25þ cells absent 0 1 1 1
Evidence of B-dependent
antidonor response
B-dependent antidonor
response with evidence
of regulation
Breg when CD25 present
BUT Bdep when CD25 absent,
1 0 5b 3c
12 13Bdep: only when CD25þ cells absent 1 3 4 3
Bdep when CD25 present, Breg
when CD25þ cells absent
0 1 1 3
No evidence of
regulation
Unregulated B-dependent
antidonor response
Bdep: when CD25þ cells present
and absent
3 0 7 3
13 11
Bdep: only when CD25þ
cells present
2 4 1 4
Not done / Not viable /
Not interpretabled
2 ND
1 NDSR
1 NDSR 5 ND
3 NDSR
3 DSR
5 ND
3 NDSR
14 9
Several other viable samples at later time points were collected and analyzed and included in Shiu et al.7 but are not considered further here.
Bdep, decrease in spot count of $20% when CD19þ cells depleted; BFC, for-cause biopsy; DSR, donor-speciﬁc reactivity; Breg, increase in spot count of $20% when CD19þ cells depleted; ELISPOT, enzyme-linked immunosorbent
spot; IFN-g, interferon-g; NDSR, no donor-speciﬁc reactivity; PBMC, peripheral blood mononuclear cells; PROTCL, protocol.
aOne of these samples was DSR (i.e., IFN-g produced by CD8-depleted PBMCs but spot count increased by >20% with B-cell depletion. Therefore, there were 7 DSR and 8 NDSR in PROTCL at time point 2.
bThree of these samples were DSR (i.e., IFN-g produced by CD8-depleted PBMCs but spot count increased by >20% with B-cell depletion. All 3 also showed increases >20% with depletion of CD25þ cells followed by reduction
(>20%) in spot count when CD19þ cells additionally depleted. Therefore, there were 14 DSR and 18 NDSR in BFC at time point 1.
cOne of these samples was DSR (i.e., IFN-g produced by CD8-depleted PBMCs but spot count increased by >20% with B-cell depletion. Both also showed increases >20% with depletion of CD25þ cells followed by reduction
(>20%) in spot count when CD19þ cells additionally depleted. Therefore, there were 11 DSR and 21 NDSR in BFC at time point 2.
dIn some samples, it was not possible to perform all 4 depletion combinations to enable interpretation based on B-cell phenotype, but classiﬁcation as DSR/NDSR was possible.
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Treatment-associated nonresponsiveness/regulation and
stability (Table 7). Changes in antidonor reactivity occurred
spontaneously in PROTCL patients, but followed treatment in
patients with BFC. To address whether treatment could
inﬂuence outcome, we selected a homogeneous subgroup of 18
patients with BFC-CAMR, chosen for 3 reasons: (i) they had no
tubulitis on biopsy; (ii) they all had ongoing and progressive
rises in creatinine, as determined by analysis of reciprocal
creatinine plots at the time of ﬁrst ELISPOT (i.e., this group
excluded 5 patients who presented with isolated proteinuria
only); and (iii) they were all treated with a protocolized treat-
ment regimen (determined clinically), consisting of addition or
optimization of tacrolimus and mycophenolate mofetil fol-
lowed by i.v. rituximabwhen oral immunotherapy was thought
to have been maximally optimized.
Three had an eGFR <20 ml/min at the time of ﬁrst
ELISPOT, so were excluded. For the remaining 15, 7 became
stable (all in “stable” subgroup) and remained stable after
treatment (Supplementary Figure S5). All 7 had time point 2
samples showing nonresponsiveness or regulation, and in 5 of
7, it was clear there had been a shift involving loss of
B-dependent responses or development of regulated anti-
donor reactivity or nonresponsiveness. In the 8 patients who
showed a continued decline in eGFR (all in the “deterio-
rating” subgroup), the picture was more complex. Inter-
pretable time point 2 ELISPOTs were available on 6. Three
had unregulated B-dependent antidonor activity at time point
2, and 2 of these had clearly lost evidence of regulation that
had been present at time point 1, including a patient (ID 635)
in whom loss of regulation by B cells followed treatment with
rituximab. The 3 remaining were nonresponsive or had
regulated antidonor activity at time point 2, but it is notable
that 2 of these had infectious complications beyond the time
point 2 ELISPOT that necessitated immunosuppression
reduction, perhaps confounding an association between their
ELISPOT patterns and outcome.
Multivariate logistic regression analysis on those patients
with viable time point 1 ELISPOTs in this subgroup was
performed. The combined model in this case included age,
sex, previous acute rejection, pretransplant dialysis time, HLA
Ab and MHC class I polypeptide-related sequence A (MICA)
status, C4d on PTC on biopsy, proteinuria, IF/TA, B-cell–
dependent antidonor IFN-g production assay, and treatment
with tacrolimus/mycophenolate mofetil/rituximab and
generated a receiver operating characteristic curve with 100%
sensitivity and 100% speciﬁcity (Figure 3c). In this uniformly
treated BFC-CAMR subgroup, ELISPOT pattern was a better
predictor of outcome than in the whole cohort and was
signiﬁcantly better than HLA Ab status.
Importance of IL-10 and regulation of IFN-g in Th-1 CD4D
cells
As described in detail in the supplementary materials,
experiments to assess whether functional Breg (increase in
Table 4 | Association between antidonor reactivity (DSR/NDSR) and patient outcomes in whole cohort
ELISPOT variable ELISPOT pattern
Number of samples
Pa
Number of samples
PaGraft failure No graft failure
Deteriorating eGFR
(£median)
Stable eGFR
(>median)
Time point 1 DSR (n ¼ 20) 3 17 0.47 11 9 0.80
NDSR (n ¼ 25) 7 18 12 13
Time point 2 DSR (n ¼ 17) 5 12 0.23 11 6 0.08
NDSR (n ¼ 30) 3 27 11 19
Change to or maintenance ofb: DSR (n ¼ 15) 5 10 0.08 10 5 0.05
NDSR (n ¼ 25) 2 23 8 17
Bold P values are those that are statistically signiﬁcant.
DSR, donor-speciﬁc reactivity; eGFR, estimated glomerular ﬁltration rate; ELISPOT, enzyme-linked immunosorbent spot; NDSR, no donor-speciﬁc reactivity.
aFisher exact test.
bIn paired samples only (i.e., samples in which ELISPOTS available at both time points); in relation to graft failure, only 7 of the 11 with graft failure had ELISPOTS at both time
points.
Table 5 | Association between antidonor reactivity based on functional B-cell phenotype and patient outcomes in whole cohort
ELISPOT variable ELISPOT pattern
Number of samples
Pa
Number of samples
PaGraft failure No graft failure
Deteriorating eGFR
(£median)
Stable eGFR
(>median)
Time point 1 No evidence of B-dependence (n ¼ 13) 2 11 0.69 4 9 0.09
Evidence of B-dependence (n ¼ 25) 6 19 16 9
Time point 2 No evidence of B-dependence (n ¼ 19) 1 18 0.11 5 14 0.03
Evidence of B-dependence (n ¼ 24) 6 18 15 9
Change to or maintenance of:b No evidence of B-dependence (n ¼ 16) 1 15 0.20 4 12 0.04
Evidence of B-dependence (n ¼ 21) 5 16 13 8
Bold P values are those that are statistically signiﬁcant.
eGFR, estimated glomerular ﬁltration rate; ELISPOT, enzyme-linked immunosorbent spot.
aFisher exact test.
bIn paired samples only (i.e., samples in which ELISPOTs available at both time points).
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spot count of $20% when CD19þ cells depleted) activity
involved IL-10 secretion indicated that there was an addi-
tional source of IL-10 in ELISPOTs besides B cells. To
explore whether T cells might themselves be making IL-
10,10,11 we selected samples with sufﬁcient cells available,
stimulated PBMC with donor material, and assessed IL-10
and IFN-g single or coexpression by CD4þ cells (Figure 5a
and 5b). In samples showing evidence of B-cell regulation
without any B-dependent antidonor responses on ELISPOT
(n ¼ 3), all CD4þ T cells expressing IFN-g also expressed
IL-10, whereas cells expressing IFN-g alone were evident
only in samples in which there was evidence of a B-depen-
dent antidonor response (n ¼ 9). The frequencies of
cytokine-positive antidonor CD4þ T cells revealed by these
a
b
20
Time point 1 Time point 2
10
0
-10
-20
-30
-40
-50
20
10
0
-10
-20
-30
-40
-50
P > 0.05
NDSR
(n = 25)
∆∆  
eG
FR
 (m
l/m
in
/1
.7
3m
eG
FR
 (m
l/m
in
/1
.7
3m
22 ))
No evidence
of B-
dependent
anti-donor
response
(n = 13)
No evidence
of B-
dependent
anti-donor
response
(n = 19)
Evidence of B-
dependent anti-
donor response
(n = 25)
Evidence of B-
dependent anti-
donor response
(n = 24)
NDSR
(n = 30)
DSR
(n = 20)
DSR
(n = 17)
P > 0.05
P = 0.05
P = 0.05
Figure 2 | Association between ELISPOT patterns and DeGFR over the course of the study in combined PROTCL and BFC group. Box
plots show median and IQR, with whiskers representing data within 1.5 of the IQR of the upper and lower quartiles, with outliers >1.5 and <3.0
IQR as þ and >3.0 IQR as *. Horizontal lines to right of box plots indicate the mean value. (a) Patterns grouped according to DSR versus NDSR
status. Time point 1: Patients with ELISPOT showing DSR have median DeGFR of 8.0 ml/min (IQR 11.6) and mean DeGFR of 9.6 ml/min (SD
12.6). Patients with NDSR have median DeGFR of 5.8 ml/min (IQR 17.9) and mean DeGFR of 8.0 ml/min (SD 14.4). P¼ 0.70 Mann-Whitney
U. Time point 2: Patients with ELISPOT showing DSR have median DeGFR of 10.1 ml/min (IQR 15.5) and mean DeGFR of 11.3 (SD 10.9)
ml/min. Patients with NDSR have median DeGFR of 3.1 ml/min (IQR 11.9) and mean DeGFR of 5.1 ml/min (SD 13.4). P ¼ 0.05 Mann-
Whitney U. NB: Analysis with 2 outliers at time point 2 removed (DeGFR 33.7 [ID 392] and 44.2 [ID 958] both in NDSR group) and replaced with
missing data reveal P ¼ 0.015. (b) Patterns group according to evidence on ELISPOT of B-cell–dependent antidonor reactivity. Time point 1:
Patients with ELISPOTs showing evidence of B-dependent antidonor IFN-g production have median DeGFR of 8.3 ml/min per 1.73 m2
(IQR 15.2) and mean DeGFR of 11.5 (SD 15.0 ml/min per 1.73 m2). Patients with ELISPOT showing no evidence of B-dependent IFN-g
production have median DeGFR of 0.9 ml/min (IQR 17.9) and mean DeGFR of 4.0 (SD 15.6) ml/min. P > 0.11 Mann-Whitney U. Time point
2: Patients with ELISPOTs showing evidence of B-dependent IFN-g production have median DeGFR of 7.9 ml/min per 1.73m2 (IQR 11.7) and
mean DeGFR of 9.6 (SD 10.9 ml/min per 1.73 m2). Patients with ELISPOT showing no evidence of B-dependent IFN-g production have
median DeGFR of 0.9 ml/min (IQR 11.6) and mean DeGFR of 4.1 (SD 15.4) ml/min. P ¼ 0.053 Mann-Whitney U. NB: Analysis with 3 outliers
at time point 2 removed (DeGFR 33.7 [ID 392] and 44.2 [ID 958] both in “No evidence of B-dependency” group, and DeGFR 35.3 [ID 635] in
“Evidence of B-dependency” group) and replaced with missing data reveal P ¼ 0.01.
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analyses were consistent with those seen in ELISPOT assays.
These data suggest that “pure” B-cell regulation in ELISPOT
associates with IL-10 expression by IFN-g–producing CD4þ
T cells.
A failure of this autocrine mechanism, resulting in Th-1
cells that produce large amounts of IFN-g, with a propor-
tional reduction in IL-10 coexpression, has been associated
with active rheumatoid arthritis (RA).12 We polyclonally
stimulated all samples from which we had sufﬁcient PBMCs
(n ¼ 16) to assess if such cells were present (Figure 5c–5e).
CD4þ cells from 4 samples produced signiﬁcantly more
IFN-g than IL-10, consistent with the proinﬂammatory
phenotype seen in patients with RA12; these samples had a
high frequency (>20%) of double-positive T cells expressing
both IFN-g and IL-10. The other 12 samples had low
frequencies of double-positive CD4þ T cells that secreted as
much IL-10 as IFN-g (Figure 5c–5e).
Importantly, all 4 samples containing the highly inﬂam-
matory Th-1 cells showed an identical pattern on antidonor
ELISPOT assay (B-cell–dependent reactivity without any
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Figure 3 | Multivariate logistic regression models in patient subgroups. ROC curves corresponding to the multivariate logistic regression
models for linked groups of predictive variable in the PROTCL biopsy (a), BFC (b), and the optimized treatment BFC-CAMR subgroup with
deteriorating creatinines (c), using generalized linear models to estimate each of the models, followed by elastic net estimate the optimal
combined algorithm, with cross validation for parameter tuning. The predictive variables included in each of the models are listed in
Supplementary Tables S5 and S6.
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Figure 4 | Associations between patterns on ELISPOT and changes in eGFR in BFC cohort. Box plots showing the association between the
results of ELISPOT assays at time of biopsy and follow-up sample with graft outcome in patients who had viable PBMC samples after thawing at
both times (n ¼ 27). (a) Patients with BFC with NDSR at time of biopsy (n ¼ 16), showing stability for those who remained NDSR (n ¼ 11)
compared with those who became DSR (n ¼ 5, P ¼ 0.003) and (b) patients with BFC with DSR at time of biopsy, showing stable eGFR for those
patients who were DSR at time of biopsy (n ¼ 11) but converted to NDSR (n ¼ 8), compared with progressive decline among those who
remained DSR (n ¼ 3, P ¼ 0.0001). (c,d) Box plots show median and IQR, with whiskers representing data within 1.5 the IQR of the upper and
lower quartiles, with outliers >1.5 and <3.0 IQR as þ and >3 IQR as *. Horizontal lines to right of box plots indicate the mean value. Graphs
shows the association between the changes in ELISPOT assays from time point 1 to time point 2 with graft outcome in patients who had
2 viable PBMC samples that could be fully interpreted (i.e., had results from CD8-, CD19-, CD25-, and CD8–CD25-depleted PBMC) (n ¼ 37).
(c) Antidonor responses. Groups correspond to those shown in Table 6 and Supplementary Table S8. Patients at time point 1 with no evidence
of B-dependent antidonor responses who maintained evidence of regulated responses at time point 2 had a median DeGFR of 1.8 ml/min
per 1.73 m2 (IQR 6.6) and mean DeGFR of 1.2ml/min per 1.73 m2 (SD 12.3). Patients with evidence of B-dependent antidonor responses
at time point 1 who maintained evidence of regulated responses at time point 2 had a median DeGFR of 5.5 ml/min per 1.73 m2 (IQR 12.9)
and mean DeGFR of 8.6 ml/min per 1.73 m2 (SD 13.7). Finally, patients who had unregulated B-cell–dependent antidonor responses at
time point 2 had a median DeGFR of 10.1 ml/min per 1.73 m2 (IQR 13.7) and mean DeGFR of 14 ml/min per 1.73 m2 (SD 12) irrespective of
the pattern they had at time point 1. P ¼ 0.036. (d) Antiviral responses. Groups correspond to those shown in Supplementary Tables S9 and S10.
Groups compared by Kruskal-Wallis test. MDRD, Modiﬁcation of Diet in Renal Disease.
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evidence of regulation by B or T cells), whereas the others
showed either no evidence of B-dependency, or regulated
B-dependent antidonor activity and appeared to respond
similarly to polyclonal stimulation (Figure 5c–5e).
All these data suggest that regulation by B cells in anti-
donor ELISPOT involves activation of an autocrine IL-10
regulatory pathway, to tip the balance from IFN-g expres-
sion by Th-1 cells to preferential IL-10 production, and that a
failure of this regulatory pathway associates with unregulated
B-cell–dependent antidonor responses.
DISCUSSION
The association between DSA and graft failure is well estab-
lished5,13,14; however, the signiﬁcant variability in clinical
phenotype associated with DSA15–18 is difﬁcult to explain.
Differences in the functional characteristics of DSA, such as
the subclass of IgG19 or the ability to ﬁx complement,20 offer
a potential explanation. However, other factors associated
with the presence of DSA might inﬂuence the progression of
pathology, rate of functional deterioration, and timing of
eventual graft failure.
HLA Abs are a marker of B-cell activation, which is a
T-cell–dependent process involving cognate interactions
between B and T cells, so it therefore follows that DSAs are
markers of “indirect” CD4þ T-cell sensitization to donor
antigens. “Indirect” in this context refers to a speciﬁc
pathway of allorecognition in which graft antigens are pro-
cessed into peptide fragments and presented on recipient
HLA class II molecules by professional antigen-presenting
cells. Indirect responses to mismatched donor HLA have
been associated with graft dysfunction and chronic rejection
in both renal21–25 and cardiac allografts.26,27 Our previous
report conﬁrmed that B cells acted as antigen-presenting cells
for indirect alloresponses in patients with CAMR,7 and also
described the complexities of antidonor reactivity, such that a
signiﬁcant proportion had evidence of active regulation of
their antidonor responses. This report addresses the
hypothesis that the activity of these cellular immune
responses is one of the signiﬁcant “other factors” that inﬂu-
ence the progression of graft dysfunction.
We conﬁrmed, as reported by others, that DSA,28 peri-
tubular capillaritis,29 and IF/TA30 on biopsy, along with
proteinuria, were all associated with graft failure. Of these
traditional factors, only DSA and proteinuria were associated
with DeGFR, although with relatively poor sensitivity and
predictive value. With regard to ELISPOT patterns, B-cell–
dependent antidonor IFN-g production was the factor most
strongly correlated with graft dysfunction in the PROTCL
subgroup. Within the BFC subgroup, correlations between
B-cell–dependent antidonor reactivity at time point 1 and
DeGFR were weaker; in this subgroup, time point 2 samples
appeared to have a stronger association with outcome, as they
did in analysis of the whole cohort. Most impressively, this
was evident in patients in whom antidonor reactivity
changed from nonresponsiveness or a regulated response at
time point 1, to an unregulated B-cell–dependent response
at time point 2: these patients showed the greatest loss of
GFR. Conversely, those with B-cell–dependent antidonor
reactivity who became nonresponsive or developed evidence
of T- or B-cell regulation, appeared to stabilize and
maintain GFR over the course of the study. This was seen
clearly as a “treatment effect” in a subset of selected pa-
tients with BFC-CAMR who received an optimized treat-
ment protocol for “creeping creatinine,” in whom the
Table 6 | Dynamic changes in antidonor ELISPOT patterns and association with outcome
Interpretation based on B-cell phenotype
Time point 2a
No response
Evidence of regulation
No evidence
of regulation
Regulated
antidonor
response without
evidence of
B-dependency
B-dependent
antidonor
response with
evidence of
regulation
Unregulated
B-dependent
antidonor response
Time point 1b
No evidence of
B-dependent
antidonor response
No response 10 patients: 8 stable, 2 deteriorating
DeGFRc 1.79 (IQR 6.63)
9 patients: 2 stable,
7 deteriorating
DeGFR 10.1
(IQR 13.7)d
Regulated antidonor response
without evidence of
B-dependency
Evidence of
B-dependent
antidonor response
B-dependent antidonor response
with evidence of regulation
18 patients: 10 stable, 8 deteriorating
DeGFR 5.54 (IQR 12.9)
Unregulated B-dependent
antidonor response
Refer to Supplementary Table S7 for full details of all patients.
eGFR, estimated glomerular ﬁltration rate; ELISPOT, enzyme-linked immunosorbent spot; IQR, interquartile range.
aSix additional patients with time point 1 samples had time point 2 samples that were either not done or not fully interpretable, so they are not included in this analysis; 3
patients had neither time point 1 or 2 samples that could be interpreted by B-cell phenotype so they are not included here.
bSix additional patients with time point 2 samples had time point 1 samples that were either not done or not fully interpretable, so they are not included in this analysis.
ceGFR in ml/min per 1.73m2.
dComparison of stable and deteriorating patients in each group: P ¼ 0.047 Fisher Exact Probability 3 x 2 test.
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Table 7 | Summary details of demographics, biopsy, and immunosuppressive treatment of optimized CAMR patients: details of the 18 patients treated with
optimization (Tac/MMF ± rituximab) for deteriorating creatinine
Patient ID PCR >50
Changes in
treatment postbiopsy
B phenotype
in ELISPOT T1
B phenotype
in ELISPOT T2 Renal outcome at 3 yr Adverse events
165 No CsA to Tac switch Regulated Bdep Breg Stable GFR, no proteinuria 0
326 Yes MMF and rituximab Bdep - no reg Regulated Bdep Stable GFR, ongoing proteinuria 0
392 Yes CsA to Tac switch Regulated Bdep NR Graft loss, 2 yr after biopsy Staph sepsis/joint infection,
7 mo after switch to Tac
397 Yes MMF Bdep - no reg Regulated Bdep Stable GFR, proteinuria resolved 0
399 No Rituximab NR NR Continued deterioration, no proteinuria 0
438 Yes MMF Bdep - no reg Regulated Bdep Stable GFR, continued proteinuria 0
635 Yes Rituximab Breg Bdep - no reg Graft loss, 22 mo after biopsy 0
739 No CsA to Tac switch NR NR Stable GFR, no proteinuria Recurrent UTI. No
serious infections.
807 (<20) Yes CsA to Tac switch - - Graft loss at 15 mo after biopsy 0
835 Yes CsA to Tac, Aza to MMF switch Breg Bdep - no reg Graft loss at 12 mo postbiopsy.
Rituximab (9 mo postbiopsy)
0
841 No CsA to Tac switch Bdep - no reg NR Stable GFR, no proteinuria 0
861 Yes CsA to Tac, Aza to MMF switch,
rituximab
Nonviable Bdep - no reg Continued deterioration,
no proteinuria
Nausea and vomiting 1
mo after rituximab.
No cause found.
Settled spontaneously.
965 No Optimized Tac, MMF levels Nonviable NR Stable GFR, no proteinuria 0
1364 Yes Rituximab NR NR Continued deterioration, continued
proteinuria
Aspergillus and Stenotrophomonas
lung infection
2 wk after ﬁrst dose of rituximab.
Not given second dose.
1404 Yes MMF. Steroids (3 mo
postbiopsy)
Rituximab (8 mo postbiopsy)
Regulated Bdep Nonviable Graft loss at 22 mo postbiopsy Pseudomonas and Klebsiella soft tissue
infection (orbital
cellulitis) 13 mo postbiopsy
(5 mo after rituximab).
2002 Yes Rituximab Bdep - no reg Not done Graft loss at 7 mo postbiopsy/rituximab 0
2006 (<20) Yes Tac, MMF, rituximab - - Graft loss at 9 mo postbiopsy 0
2010 (<20) Yes CsA to Tac switch - - Graft loss at 16 mo postbiopsy 0
Rows highlighted in gray are the patients who stabilized their renal function after treatment. Refer to Supplementary Figure S6 for the plots of Modiﬁcation of Diet in Renal Disease and change in estimated GFR. Deteriorating GFR
at time of biopsy conﬁrmed by analysis of 1/creatinine plot. Stability and continued deterioration after 3 years were conﬁrmed also on analysis of 1/creatinine plots.
Bdep - no reg, unregulated B-dependent antidonor response; Breg, regulated antidonor response without evidence of B-dependency; CAMR, chronic antibody-mediated rejection; ELISPOT, enzyme-linked immunosorbent spot;
GFR, glomerular ﬁltration rate; MMF, mycophenolate mofetil; NR, nonresponsive; PCR, protein-to-creatinine ratio; regulated Bdep, B-dependent antidonor response with evidence of regulation; T1, time point 1; T2, time point 2; CsA,
ciclosporin A; Tac, tacrolimus; Aza, azathioprine; UTI, urinary tract infection. ELISPOT responses for patients 807, 2006, 2010 are not provided at T1 or T2 as they had eGFR <20 and were therefore excluded from analysis.
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predictive value of the time point 1 ELISPOT pattern was
enhanced and was better than HLA Ab status at predicting
DeGFR. We believe the main reason why univariate asso-
ciations were not seen in subgroup analyses at all time
points was the small number of patients in our analysis,
compounded by the fact that ELISPOT interpretations were
complex, so that when they were deﬁned according to the
patterns revealed by sequential depletion of CD25 /CD19
cells, associations were mostly evident only in analysis of
the whole group.
Nevertheless, multivariate testing indicated the ELISPOT
pattern to be an independent factor that predicted changes in
eGFR in both PROTCL and BFC groups, as demonstrated by
the superior AUCs obtained from our prediction modeling
when ELISPOT patterns were included. Our statistical
methodology was chosen so we could estimate the predictive
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Figure 5 | Flow cytometric analysis of Th-1 cytokine production. (a,b) Donor antigen-speciﬁc IFN-g production by CD4þ T cells: comparison
of subgroups according to functional B-cell phenotype on ELISPOT. CD8-depleted PBMCs were stimulated with donor antigen under same
conditions as in ELISPOT, then assayed by ﬂow cytometry by using a cytokine capture system. White bars: Samples (n ¼ 8) from patients with
ELISPOT pattern showing evidence of B-dependent antidonor IFN-g production (with or without evidence of regulation). Black bars: Samples
(n ¼ 3) from patients with ELISPOT pattern showing only suppression of antidonor IFN-g production by B cells with NO evidence of B-
dependent responses. (a) Shows the percentage of CD4þ cells expressing only IFN-g (IFN-g þ IL-10) or coexpressing with IL-10 (IFN-g þ IL-
10þ). (b) Shows the comparison of the percentage of total cells expressing IFN-g/% total cells expressing IL-10. (c–e) Polyclonal stimulation with
anti-CD3/anti-CD46 monoclonal antibodies: comparison of subgroups according to functional B-cell phenotype on ELISPOT. White bars:
Samples (n ¼ 4) in which antidonor-speciﬁc ELISPOT showed only suppression of antidonor IFN-g production by B cells with NO evidence
of B-dependent responses. Black bars: Samples (n ¼ 8) in which antidonor-speciﬁc ELISPOT showed evidence of a regulated B-dependent
antidonor response. Gray bars: Samples (n ¼ 4) in which antidonor-speciﬁc ELISPOT showed evidence of an unregulated B-dependent anti-
donor response. (c) Percentage of CD4þ cells staining for IFN-g alone (IFN-g þ IL-10) compared with cells staining for both (IFNg þ IL-10þ).
(d) Median ﬂuorescence intensity of staining for IFN-g or IL-10 in the single-positive (IFNg þ IL-10) or double-positive (IFNg þ IL-10þ) CD4þ
populations as indicated. (e) Ratio of mean ﬂuorescence intensity of IFN-g staining to IL-10 staining in the double-positive (IFN-g þ IL-10þ)
population in (d). *P < 0.05 by Mann-Whitney U test.
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accuracy of all variables irrespective of their P values; where
individual variables were selected for testing, elastic net
regression, tuned via cross-validation, was used because of the
small sample sizes.
These data provide the ﬁrst potential explanation for the
ﬁndings of Wiebe et al.,31 who described patients with DSA,
who were compliant with immunosuppressive medication
and had stable graft function, suggesting that maintaining
“control” of T and B cells with conventional immunosup-
pression is sufﬁcient to achieve stability of function in some
patients with DSA. They are also compatible with the recent
report from Shabir et al.,32 who described a link between
stable graft function and preserved peripheral transitional
B-cell proportions, even in a small number of patients who
developed de novo DSA, although we were unable to correlate
a speciﬁc surface B-cell phenotype with the functional
phenotype revealed by ELISPOT.7 Our results also provide a
basis for understanding the reports of how enhanced
immunosuppression can stabilize function in patients with
CAMR. Theruvath et al.33 reported 12-month stabilization of
kidney function in 3 of 4 patients with CAMR after transfer
onto tacrolimus and mycophenolate mofetil and a short
course of prednisolone. In addition, several studies have
reported successful stabilization after B-cell depletional
therapy,34–36 supporting the hypothesis that underlying
cellular responses are contributing to functional deterioration
in these patients.
Eight of our patients received rituximab, but no deﬁnitive
conclusions from these small numbers can be made. How-
ever, as well as patient 635 (highlighted previously in this
article), who lost evidence of B-cell regulation after rituximab,
another patient (326) stabilized eGFR after rituximab in
association with development of a regulated antidonor
response (there was no change in the median ﬂuorescence
intensity of DSA assessed by Luminex [xMAP assay (Ther-
moﬁsher, California, USA)] in either patient [Supplementary
Table S1c and c]). Both cases suggest that response to ritux-
imab might be informed by knowledge of ELISPOT patterns
pretreatment.
It is important to state, as we have before,7 that we were
not able to purify putative regulatory T or B cells from pa-
tients due to lack of cells. Therefore, the conclusions made are
based on indirect evidence of regulation, on depleting speciﬁc
lymphocyte subsets, rather than a direct demonstration of
suppressive activity from puriﬁed, and then in vitro assessed
cell subpopulations. We presented our ﬂow cytometric anal-
ysis of these samples in our earlier article last year, and found
no associations between the proportions of B-cell subsets,
including transitional or naïve cells and ELISPOT patterns or
outcome,7 although we acknowledge that others working in
this ﬁeld have shown associations between rejection and
particular B-cell subsets, including transitional B cells.32,37,38
In addition, the associations reported in this article need to
be validated in different cohorts of patients, ideally with work
to assess the reproducibility of the assays within patients and
to more carefully document how patterns change over time.
Importantly, for the ﬁrst time, we have attempted to link
antigen-speciﬁc indirect alloresponses with mechanisms by
which IFN-g production is regulated in Th-1 CD4þ T cells.
Physiological regulation of these cells, by IL-10, is known to
be essential, as unchecked IFN-g production results in severe
tissue damage, as illustrated by the responses to Listeria or
Trypanosoma disease in IL-10–deﬁcient mice.10 Although
multiple cell types can make IL-10, that made by the Th-1
cells themselves39 is the major in vivo source40 and critical
to providing regulatory feedback, via antigen-presenting cells
and T cells themselves, to prevent inappropriate Th-1–driven
immunopathology.41 Aligning with this model, we showed
that an anti–IL-10 antibody caused signiﬁcant increase in the
frequency of IFN-g producing spots in ELISPOT, even in the
absence of B cells, and additionally, that in CD8-depleted
samples showing evidence of only a B-regulated response,
Th-1 cells stimulated by donor antigen only made IFN-g in
the context of coexpression with IL-10. We have not
attempted to assess the predominant source of IL-10 in our
assays, and our data cannot exclude an important role for
B-cell–derived IL-10 in regulation of antidonor alloresponses,
as others working in this area have shown.37,42,43
Abnormalities of IL-10 switching mediated by CD46
signaling have been associated with excessive IFN-g produc-
tion by Th1 cells from synovial ﬂuid of patients with RA.12
T cells from patients with active RA fail to shut down
IFN-g production on CD46-activation, and, perhaps coun-
terintuitively, have high proportions of IFN-g þ IL-10 þ
double-positive cells, but these express a very large amount of
IFN-g compared with T cells from healthy individuals.10,12
Using an in vitro system involving polyclonal stimulation
through CD46,44 we found cells similar to those described in
patients with RA in 4 of 16 samples, all of which demon-
strated the same pattern of antidonor response (unregulated
B-cell–dependent reactivity), whereas the other 12 samples
showing evidence of regulation resembled responses seen in
healthy controls.12
These data imply, for the ﬁrst time, that functional sup-
pression by B cells in ELISPOT activates this IL-10 autocrine
pathway of regulation to restrict IFN-g production by Th-1
cells. Moreover, inability to switch off IFN-g production via
this regulatory mechanism associates with a speciﬁc pattern of
unregulated antidonor response that, as we have demon-
strated here, is associated with a greater loss of renal function
over time. Better understanding of this regulatory mechanism
may lead to the development of more sophisticated treat-
ments for chronic rejection.
In summary, our analysis of the cell-mediated IFN-g
production by PBMCs against donor antigens has generated
2 important and novel ﬁndings. First, a signiﬁcant associa-
tion between patterns of antidonor ELISPOT reactivity and
eGFR outcomes, with evidence that treatment to inﬂuence
antidonor responses can affect patient outcomes: these
ﬁndings support the hypothesis we set out to test, that cell-
mediated immunity has a strong inﬂuence on deterioration
in patients with CAMR. Second, we have deﬁned a novel link
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between B-cell regulation of IFN-g production and an
IL-10–dependent autocrine mechanism regulating Th-1
CD4þ T cells, with the implication that manipulation of
this mechanism might signiﬁcantly affect the evolution of
indirect alloresponses, and ultimately, on long-term allograft
survival.
MATERIALS AND METHODS
Methodology is exactly as described in a previous report.7 Full details
are given in the Methods section of the Supplementary Materials and
Methods. Brief descriptions are given here.
Experimental design and recruitment
The study was performed as part of a large observational study
looking at the importance of HLA antibodies posttransplantation,
the protocol of which was approved by the Hammersmith, Queen
Charlotte’s, and Chelsea and Acton Hospitals Research Ethics
Committees (2002/6452) and conformed to the 1964 Declaration of
Helsinki and subsequent amendments. All participants gave written
informed consent before inclusion. Calculation of eGFR, DeGFR,
and details of blood collection and processing is described in the
Methods section of the supplementary materials.
ELISPOT assay
IFN-g ELISPOT plates (Mabtech AB, Nacka, Sweden) precoated
with primary IFN-g Ab were blocked for 2 hours with “complete
medium” (AIM-V medium/10% human AB serum from Life Tech-
nologies [Paisley, UK]) before addition of 4 x 105 responder PBMCs
per well in 100 ml complete medium with donor antigens. PBMCs
were prepared according to standard laboratory protocols. Controls
and source of donor antigen are described in detail in the Methods
section of the supplementary materials.
Statistical analysis
Statistical analyses were performed by using R.45 Two-sided tests
were used throughout, and a P < 0.05 was considered statistically
signiﬁcant in univariate statistical testing. Group differences were
assessed by using Fisher c2 test for categorical variables, Wilcoxon
rank-sum (Mann-Whitney) or Kruskal-Wallis tests for non-normally
distributed continuous variables, and t-test for normally distributed
continuous variables (for paired or unpaired samples as appro-
priate). For prediction analysis, we estimated generalized linear
models for predeﬁned groups of predictive variables. Only baseline
variables were added to generalized linear prediction models, and
thus ﬁxed effects only models were ﬁtted. The estimated predicted
probability of outcome was then used to build a receiver operating
characteristic curve, and estimate the AUC, sensitivity, and speci-
ﬁcity.46 To obtain the optimal combination of predictors of outcome,
we used elastic net models. Elastic net is a regularized regression
method in which a penalty is imposed on the regression coefﬁcients,
which is a combination of the penalties used in lasso and ridge
regression. Elastic net enables selection of predictors (unlike ridge
regression, which would moderate coefﬁcients but not make
them 0), and can handle and select groups of correlated predictors
(unlike lasso, which would select only 1 of a group of correlated
predictors, and drop the rest).47
For the analysis of patterns of change in eGFR over time in
patients with and without baseline DSR, we ﬁtted linear mixed-
effects models. Separate models were ﬁtted for patients with and
without baseline DSR. The model included an intercept, main
effects, and interaction between study time point (from prebiopsy to
3-years’ follow-up) and DSR status at time point 2 as ﬁxed effects, as
well as a random intercept for the subject.
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Figure S1. Lack of association between PTC score and DeGFR and
between IF/TA and DeGFR over the course of the study in combined
PROTCL and BFC group. (A) Box plots show median with IQR with
whiskers showing upper and lower limits of DeGFR. Combined group
includes all PROTCL and BFC patients, except 9 patients with BFC who
either had missing follow-up data (n ¼ 2) or eGFR #20 ml/min per
1.73 m2 at time of biopsy (n ¼ 7). Patients with PTC score <1 have
median DeGFR of 6.85 ml/min per 1.73 m2 (IQR 12.4) and mean
DeGFR of 8.7 ml/min per 1.73 m2 (SD 13.1). Patients with PTC
score $1 have median DeGFR of 8.0 ml/min per 1.73 m2 (IQR 16.7)
and mean DeGFR of 7.2 ml/min per 1.73 m2 (SD 15.1). *Mann-
Whitney U test. (B) Graph shows lack of correlation between IF/TA %
on biopsy and DeGFR for each of the patients (n ¼ 52) included in
this analysis.
Figure S2. Association between DSA and DeGFR over the course of
the study in combined cohort. Box plots show median with IQR with
whiskers showing upper and lower limits of DeGFR. Combined group
includes all PROTCL and BFC patients, except 9 patients with BFC who
either had missing follow-up data (n ¼ 2), or eGFR #20 ml/min
1.73 m2 at time of biopsy (n ¼ 7). Time point 1: Patients with No DSA
or DSA with cumulative mean ﬂuorescence intensity of <1000
(n ¼ 35) have median DeGFR of 3.19 ml/min per 1.73 m2 (IQR 12.3)
and mean DeGFR of 6.24 ml/min 1.73 m2 (SD 13.4). Patients with
DSA with cumulative mean ﬂuorescence intensity >1000 (n ¼ 17)
have median DeGFR of 11.4 ml/min per 1.73 m2 (IQR 10.7) and
mean DeGFR of 12.4 ml/min per 1.73 m2 (SD 13.3). Time point 2:
Patients with No DSA or DSA with cumulative mean ﬂuorescence
intensity of <1000 (n ¼ 34) have median DeGFR of 3.69 ml/min
per 1.73 m2 (IQR 12.4) and mean DeGFR of 5.68 ml/min/1.73 m2
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(SD 11.9). Patients with DSA with cumulative mean ﬂuorescence
intensity >1000 have median DeGFR of 9.9 ml/min per 1.73 m2
(IQR 15) and mean DeGFR of 13.0 ml/min per 1.73 m2 (SD 16).
**Mann-Whitney U test.
Figure S3. Box plots show median with IQR with whiskers showing
upper and lower limits of DeGFR in PROTCL (A) and BFC (B)
subgroups. Time point 1: PROTCL patients with DSR have median
DeGFR of 8.34 ml/min per 1.73 m2 (IQR 17.4) and mean DeGFR
of 17.3 ml/min per 1.73 m2 (SD 17.4), compared with those with
NDSR who have a median DeGFR of 2.03 ml/min per 1.73 m2 (IQR
6.2) and mean DeGFR of 2.38 ml/min per 1.73 m2 (SD 4.9). Patients
with BFC with DSR have median DeGFR of 6.4 ml/min per 1.73 m2
(IQR 11.7) and mean DeGFR of 7.1 ml/min per 1.73 m2 (SD 10.7),
compared with those with NDSR who have median DeGFR of –9.9
ml/min per 1.73 m2 (IQR 20.1) and mean DeGFR of 10.3 ml/min per
1.73 m2 (SD 17.1). Actual P ¼ 0.46. Time point 2: PROTCL patients
with DSR have median DeGFR of 4.5 ml/min per 1.73 m2 (IQR 7.2)
and mean DeGFR of 4.6 ml/min per 1.73 m2 (SD 5.4), compared to
those with NDSR who have median DeGFR of 4.2 ml/min per
1.73 m2 (IQR 15.8) and mean DeGFR of 10.9 ml/min per 1.73 m2
(SD 15.5). Patients with BFC with DSR have median DeGFR
of 12.7ml/min per 1.73 m2 (IQR 13.5) and mean DeGFR of 13.5
ml/min per 1.73 m2 (SD 14.6), compared with those with NDSR who
have median DeGFR of –2.5 ml/min per 1.73 m2 (IQR 12.3) and mean
DeGFR of 2.4 ml/min per 1.73 m2 (SD 12.1). Actual P ¼ 0.01.
**Mann-Whitney U test.
Figure S4. Box plots show median with IQR with whiskers showing
upper and lower limits of DeGFR in PROTCL (upper panel) and BFC
(lower panel) subgroups. Time point 1: PROTCL patients with no
evidence of B-dependent antidonor responses have median DeGFR
of þ1.5 ml/min per 1.73 m2 (IQR 3) and mean DeGFR of 0.54 ml/min
per 1.73 m2 (SD 2.6), compared with those with evidence of
B-dependent antidonor reactivity, who have a median DeGFR of 7.7
ml/min per 1.73 m2 (IQR 11.7) and mean DeGFR of 13.8 ml/min
per 1.73 m2 (SD 15.4). Patients with BFC with no evidence of
B-dependent antidonor responses have median DeGFR of 11.1
ml/min per 1.73 m2 (IQR 27.6) and mean DeGFR of 6.9 ml/min
per 1.73 m2 (SD 19.7), compared with those with evidence of
B-dependent antidonor reactivity, who have median DeGFR of –9.7
ml/min per 1.73 m2 (IQR 12) and mean DeGFR of 10.3 ml/min per
1.73 m2 (SD 12.4). Actual P¼ 0.88 by Mann-Whitney U. Time point 2:
PROTCL patients with no evidence of B-dependent antidonor re-
sponses have median DeGFR of 1.7 ml/min per 1.73 m2 (IQR 3.9)
and mean DeGFR of 7.7 ml/min per 1.73 m2 (SD 18), compared
with those with evidence of B-dependent antidonor reactivity, who
have a median DeGFR of 6.8 ml/min per 1.73 m2 (IQR 5.7) and mean
DeGFR of 7.7 ml/min per 1.73 m2 (SD 8.2). Actual P ¼ 0.22 by
Mann-Whitney U. Patients with BFC with no evidence of B-dependent
antidonor responses have median DeGFR of 0.27 ml/min per
1.73 m2 (IQR 13.4) and mean DeGFR of 2 ml/min per 1.73 m2
(SD 14.8), compared with those with evidence of B-dependent
antidonor reactivity, who have median DeGFR of –9.1 ml/min per
1.73 m2 (IQR 13.6) and mean DeGFR of 9.6 ml/min per 1.73 m2
(SD 13.8). Actual P ¼ 0.1 by Mann-Whitney U. **Mann-Whitney U test.
Figure S5. Changes in eGFR in CAMR subgroup who received
protocolized treatment. Box plots showing median with IQR with
whiskers showing upper and lower limits of the Modiﬁcation of Diet
in Renal Disease (MDRD) eGFR (A) and DeGFR (B) in the subgroup of
patients with CAMR (n¼15) characterized by having eGFR >20 at
time of biopsy, no tubulitis on histological examination of biopsy, and
identiﬁed as having an ongoing and progressive rise in creatinine, as
determined by analysis of reciprocal creatinine plots at the time of
ﬁrst ELISPOT. All were treated with a protocolized treatment regimen,
details of which are shown in Table 5. Seven patients stabilized
(identiﬁed by boxes joined with coarse dotted line). Eight patients
failed to stabilize (identiﬁed by boxes joined by ﬁne dotted line).
Analysis excludes 3 patients who had eGFR <20 at time of biopsy (see
Table 5). The differences in the ELISPOT patterns in these 2 subgroups
is described in the text. *Points at which values are statistically
signiﬁcant (P < 0.05) by Mann-Whitney U test.
Figure S6. Experiments to address the role of IL-10 in control of IFN-g
production. Anti–IL-10 monoclonal antibody (to inhibit IL-10) or
isotype control was added into the CD8-depleted leukocyte “cone”
samples (white, individual 1; gray, individual 2; black, individual 3), 2
showing consistent suppression of IFN-g production by B cells (white,
gray bars) and the third showing B-dependent IFN-g production
(black bars). Frequencies >50/million CD4þ T cells (dotted line on
graph) were deﬁned as positive. SFC, spotforming cells. The impact of
the antibody after B-cell depletion suggests there is an additional
source of IL-10, other than B cells, in the PBMC.
Table S1a. Patients excluded from analysis of outcomes because
eGFR at ﬁrst ELISPOT #20 ml/min per 1.73 m2 OR because follow-up
data missing.
Table S1b. Basic demographics, biopsy results, and eGFR data on the
“stable” subgroup with DeGFR >median in either PROTCL or BFC
group.
Table S1c. Basic demographics, biopsy results, and eGFR data on the
“deteriorating” subgroup with DeGFR #median in either PROTCL or
BFC group.
Table S2a. Impact of reducing threshold for positive DSA to >0.
Table S2b. Lack of association between DSA and outcomes in BFC
cohort only.
Table S2c. Lack of association between DSA and outcomes in
PROTCL cohort only.
Table S3. Associations between ELISPOT pattern and outcomes in
PROTCL (A) and BFC (B) subgroups.
Table S4. Association between antidonor reactivity based on
functional B-cell phenotype and patient outcomes in PROTCL (A) and
BFC (B) cohorts.
Table S5. PROTCL cohort – factors used for prediction modeling.
Table S6. BFC cohort – factors used for prediction modeling.
Table S7. Dynamic changes in ELISPOT patterns.
Table S8. Dynamic changes in antiviral antigen ELISPOT patterns and
lack of association with outcome.
Table S9. Dynamic changes in antiviral ELISPOT patterns.
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.
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